Episode 1 Ventures’ Post

Our portfolio company Sable Bio has just published a piece about their journey tackling one of healthcare's most critical challenges: making drug development safer and more efficient through augmented intelligence. 30% of clinical trials fail due to unforeseen toxicity, and Alex de Giorgio and Josh Almond-Thynne are making great progress transforming drug safety assessment. 2025 is going to be a huge year!

To view or add a comment, sign in

Explore content categories